Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous,...
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
About this item
Full title
Author / Creator
Publisher
Macclesfield: Taylor & Francis Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Macclesfield: Taylor & Francis Ltd
Subjects
More information
Scope and Contents
Contents
Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Ther Clin Risk Manag. 2022;18:699–719. The authors have advised there is an error in Table 1 on page 712. The value “1200 mg” in the Neisseria meningitidis vaccination row for the Induction Phase, Week 4 column for Refractory gMG Adult (≥18 years of age) Dosing Schedule, should read “900 mg”. This...
Alternative Titles
Full title
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b30aab5f637049829b751818342499ce
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b30aab5f637049829b751818342499ce
Other Identifiers
ISSN
1178-203X,1176-6336
E-ISSN
1178-203X
DOI
10.2147/TCRM.S384532
